Cited In for PMID: 29894693

Year	Number of Results
2018	8
2019	19
2020	27
2021	31
2022	28
2023	33
2024	7

1

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality.

Gogola E, Duarte AA, de Ruiter JR, Wiegant WW, Schmid JA, de Bruijn R, James DI, Guerrero Llobet S, Vis DJ, Annunziato S, van den Broek B, Barazas M, Kersbergen A, van de Ven M, Tarsounas M, Ogilvie DJ, van Vugt M, Wessels LFA, Bartkova J, Gromova I, Andújar-Sánchez M, Bartek J, Lopes M, van Attikum H, Borst P, Jonkers J, Rottenberg S. Gogola E, et al. Cancer Cell. 2018 Jun 11;33(6):1078-1093.e12. doi: 10.1016/j.ccell.2018.05.008. Cancer Cell. 2018. PMID: 29894693 Free article.

2

DePARylation is critical for S phase progression and cell survival.

Nie L, Wang C, Huang M, Liu X, Feng X, Tang M, Li S, Hang Q, Teng H, Shen X, Ma L, Gan B, Chen J. Nie L, et al. Elife. 2024 Apr 5;12:RP89303. doi: 10.7554/eLife.89303. Elife. 2024. PMID: 38578205 Free PMC article.

3

Functional Homologous Recombination (HR) Screening Shows the Majority of BRCA1/2-Mutant Breast and Ovarian Cancer Cell Lines Are HR-Proficient.

Meijer TG, Martens JWM, Prager-van der Smissen WJC, Verkaik NS, Beaufort CM, van Herk S, Robert-Finestra T, Hoogenboezem RM, Ruigrok-Ritstier K, Paul MW, Gribnau J, Bindels EMJ, Kanaar R, Jager A, van Gent DC, Hollestelle A. Meijer TG, et al. Cancers (Basel). 2024 Feb 10;16(4):741. doi: 10.3390/cancers16040741. Cancers (Basel). 2024. PMID: 38398132 Free PMC article.

4

FSP1 inhibition enhances olaparib sensitivity in BRCA-proficient ovarian cancer patients via a nonferroptosis mechanism.

Miao H, Meng H, Zhang Y, Chen T, Zhang L, Cheng W. Miao H, et al. Cell Death Differ. 2024 Feb 19. doi: 10.1038/s41418-024-01263-z. Online ahead of print. Cell Death Differ. 2024. PMID: 38374229

5

PARG-deficient tumor cells have an increased dependence on EXO1/FEN1-mediated DNA repair.

Andronikou C, Burdova K, Dibitetto D, Lieftink C, Malzer E, Kuiken HJ, Gogola E, Ray Chaudhuri A, Beijersbergen RL, Hanzlikova H, Jonkers J, Rottenberg S. Andronikou C, et al. EMBO J. 2024 Mar;43(6):1015-1042. doi: 10.1038/s44318-024-00043-2. Epub 2024 Feb 15. EMBO J. 2024. PMID: 38360994 Free PMC article.

6

Small molecule agents for triple negative breast cancer: Current status and future prospects.

Ou Y, Wang M, Xu Q, Sun B, Jia Y. Ou Y, et al. Transl Oncol. 2024 Mar;41:101893. doi: 10.1016/j.tranon.2024.101893. Epub 2024 Jan 29. Transl Oncol. 2024. PMID: 38290250 Free PMC article. Review.

7

Polyadenosine diphosphate-ribose polymerase inhibitors: advances, implications, and challenges in tumor radiotherapy sensitization.

Zhang Y, Liang L, Li Z, Huang Y, Jiang M, Zou B, Xu Y. Zhang Y, et al. Front Oncol. 2023 Dec 4;13:1295579. doi: 10.3389/fonc.2023.1295579. eCollection 2023. Front Oncol. 2023. PMID: 38111536 Free PMC article. Review.

8

Development of Homologous Recombination Functional Assays for Targeting the DDR.

Oswald AJ, Gourley C. Oswald AJ, et al. Cancer Treat Res. 2023;186:43-70. doi: 10.1007/978-3-031-30065-3_4. Cancer Treat Res. 2023. PMID: 37978130

9

ADP-ribose contributions to genome stability and PARP enzyme trapping on sites of DNA damage; paradigm shifts for a coming-of-age modification.

Rouleau-Turcotte É, Pascal JM. Rouleau-Turcotte É, et al. J Biol Chem. 2023 Dec;299(12):105397. doi: 10.1016/j.jbc.2023.105397. Epub 2023 Oct 28. J Biol Chem. 2023. PMID: 37898399 Free PMC article. Review.

10

Combination Treatment Strategies to Overcome PARP Inhibitor Resistance.

Soung YH, Chung J. Soung YH, et al. Biomolecules. 2023 Oct 3;13(10):1480. doi: 10.3390/biom13101480. Biomolecules. 2023. PMID: 37892162 Free PMC article. Review.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Results by year

Text availability

Article attribute

Article type

Publication date

147 results

Results by year